Haemonetics Corp.

Haemonetics is a healthcare company. The company has three product categories: Plasma, which includes plasma collection devices and disposables, plasma donor management software, and anticoagulant and saline sold to plasma customers; Blood Center, which includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software; and Hospital, which is comprised of Hemostasis Management and Cell Processing products, includes devices and methodologies for measuring coagulation characteristics of blood, surgical blood salvage systems, blood cell processing systems, disposables and blood transfusion management software.
  • TickerHAE
  • ISINUS4050241003
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States
HAE Haemonetics Cor... (Health Care)

Haemonetics Corp: 1 director

A director at Haemonetics Corp sold 4,293 shares at 66.600USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

HAE Haemonetics Cor... (Health Care)

An unfavourable environment weighs on HAEMONETICS, which sees a downgr...

The independent financial analyst theScreener just requalified the general evaluation of HAEMONETICS (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date June 1, 2021, the closing price was USD 57.02 and its target price was estimated at USD 48.70.

HAE Haemonetics Cor... (Health Care)

Haemonetics Corp: 1 director

A director at Haemonetics Corp sold 4,293 shares at 66.600USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

HAE Haemonetics Cor... (Health Care)

An unfavourable environment weighs on HAEMONETICS, which sees a downgr...

The independent financial analyst theScreener just requalified the general evaluation of HAEMONETICS (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date June 1, 2021, the closing price was USD 57.02 and its target price was estimated at USD 48.70.

HAE Haemonetics Cor... (Health Care)

Haemonetics Corp: 1 director

A director at Haemonetics Corp sold 4,293 shares at 66.600USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

HAE Haemonetics Cor... (Health Care)

An unfavourable environment weighs on HAEMONETICS, which sees a downgr...

The independent financial analyst theScreener just requalified the general evaluation of HAEMONETICS (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date June 1, 2021, the closing price was USD 57.02 and its target price was estimated at USD 48.70.

HAE Haemonetics Cor... (Health Care)

Haemonetics Corp: 1 director

A director at Haemonetics Corp sold 4,293 shares at 66.600USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

HAE Haemonetics Cor... (Health Care)

An unfavourable environment weighs on HAEMONETICS, which sees a downgr...

The independent financial analyst theScreener just requalified the general evaluation of HAEMONETICS (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date June 1, 2021, the closing price was USD 57.02 and its target price was estimated at USD 48.70.

HAE Haemonetics Cor... (Health Care)

Haemonetics Corp: 1 director

A director at Haemonetics Corp sold 4,293 shares at 66.600USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

HAE Haemonetics Cor... (Health Care)

An unfavourable environment weighs on HAEMONETICS, which sees a downgr...

The independent financial analyst theScreener just requalified the general evaluation of HAEMONETICS (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date June 1, 2021, the closing price was USD 57.02 and its target price was estimated at USD 48.70.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch